z-logo
Premium
Treatment of chronic dilated cardiomyopathy with immunoadsorption using the staphylococcal A‐Agarose column: A comparison of immunoglobulin reduction using two different techniques
Author(s) -
Burgstaler Edwin A.,
Cooper Leslie T.,
Winters Jeffrey L.
Publication year - 2007
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.20137
Subject(s) - immunoadsorption , medicine , apheresis , antibody , dilated cardiomyopathy , antigen , heart transplantation , adverse effect , gastroenterology , immunology , surgery , cardiology , transplantation , heart failure , platelet
Auto‐antibodies to myocardial antigens have been implicated in the pathogenesis of chronic dilated cardiomyopathy (DCM). A protein A immunoadsorption affinity column system was used to remove IgG antibodies, particularly IgG3. Two techniques, the standard technique (T‐1) used for removal of IgG Factor VIII inhibitors and a technique (T‐2) designed to enhance IgG3 removal and address issues in venous access, minimize positive fluid balance, and adverse reactions were compared. A total of four patients were treated, two patients were treated for 5 consecutive days with each technique. T‐2 resulted in larger, but not significantly so, IgG3 reduction (70% and 63%) than T‐1 (53% and 59%). Both techniques lowered total IgG levels by ≥93%. Because of venous access problems, 60% of T‐1 procedures reached the plasma volume target versus 100% for T‐2. Positive fluid balance was significantly lower for T‐2 (+507 ± 465) ml versus T‐1 (+2,206 ± 724) ml. Overall adverse event (AE) rate (T‐1:16, T‐2:15) was similar between the techniques but demonstrated a statistically significant difference in the types of reactions that occurred. All AE were mild in nature, common to other apheresis procedures, and were easily managed. This small study, demonstrated that a modified technique (T‐2) with superior fluid balance should be used when treating DCM with the Immunosorba® system. J. Clin. Apheresis. 2007 © 2007 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom